NCT02152982 2026-04-13
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
National Cancer Institute (NCI)
Global Coalition for Adaptive Research
National Cancer Institute (NCI)
Beijing Pearl Biotechnology Limited Liability Company
Everfront Biotech Co., Ltd.